10. Clinical Data Pancreatic Cancer Group N Six Month Survival Rate (%) p One Year Survival Rate ( ％ ) p +Adjuvant 25 64 ＞ 0.05 28 ＜ 0.05 -Adjuvant 20 45 5
11. Clinical Data — NSCLC* *Patients were treated with intratumoral therapy, followed by supportive treatment (radiotherapy and EP Chemotherapy ： CBP 0.3 d 1 ， VP-16 0.1 d 1 ～ 4 ) Group Stage N Median Survival Time (M) Six Month Survival Rate (%) One Year Survival Rate (%) - Adjuvant II 10 6.33 50 30 III 20 5.52 45 20 IV 12 4.9 41.67 33.33 Sum 42 7.59 45.23 26.19 + Adjuvant II 8 11.47 100 50 III 33 11.9 69.7 42.42 IV 11 9.77 81.82 45.45 Sum 52 12.66 76.36 45.45
12. Clinical Data — NSCLC** **Patients were treated with intratumoral therapy alone Group N Mean Survival Time (M) Median Survival Time (M) Six Month Survival Rate ( ％ ) One Year Survival Rate ( ％ ) -Adjuvant Ⅰ 2 22.5 4 50 50 Ⅱ 2 4.5 4.5 0 0 Ⅲ 6 3.33 2 16.67 0 Ⅳ 4 6.15 4.5 50 25 Sum 14 7.04 3.5 28.57 14.29 +Adjuvant Ⅰ 5 25.5 13 60 60 Ⅱ 2 14 11 50 50 Ⅲ 11 18.8 10 72.72 45.45 Ⅳ 7 2.86 1 28.57 0 Sum 25 15.29 9 64 36
13. Clinical Data Relapsed NSCLC Patients were treated with intratumoral therapy, followed by supportive treatment Group N Mean Survival Time (M) Median Survival Time (M) One Year Survival Rate (% ） -Adjuvant 34 7.40 5.32 5.88 +Adjuvant 60 11.99 9.36 20.34
14.
15. Clinical Data Side Effect Evaluation SE Sum N ％ Ⅰ Ⅱ Ⅲ Ⅳ Nausea/Vomit 120 6 6 0 0 10 Hair Loss 120 0 0 0 0 0 Leukopenia 120 2 1 1 0 3.33
![New Hope for Cancertherapy: A New Drug Combination for Chemoimmunotherapy ,[object Object]](https://image.slidesharecdn.com/random-100521221509-phpapp02/85/-1-320.jpg)
![Company Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)